Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:47:51.276Z.
Calculation as of: 2026-10-06T21:47:51.276Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a98ef6549bf85b46c4ba181efc1584300b0c5a2a31302d891700dc780dc00a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2003-11-19.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$10.45M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.00M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.08M
EV/EBITDA Ratio
N/A
TTM Avg
12.81x
3Y Avg
12.81x
5Y Avg
12.81x
Market Cap
$11.12M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pluri Inc. (PLUR) | $10.68M | N/A | N/A | N/A | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | N/A | N/A | N/A |
| BioVie Inc. (BIVI)vs › | $10.86M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.94M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | N/A | 12.81x | 12.81x | 12.81x |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.21M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2003-11-19 | 985.33x |
| 2003-11-18 | 996.18x |
| 2003-11-17 | 1061.25x |
| 2003-11-14 | 1050.40x |
| 2003-11-13 | 1082.94x |
| 2003-11-12 | 1050.40x |
| 2003-11-11 | 1028.71x |
| 2003-11-10 | 1028.71x |
| 2003-11-07 | 963.64x |
| 2003-11-06 | 1082.94x |
| 2003-11-05 | 1082.94x |
| 2003-11-04 | 1072.09x |
| 2003-11-03 | 1028.71x |
| 2003-10-31 | 1082.94x |
| 2003-10-30 | 1028.71x |
| 2003-10-29 | 1028.71x |
| 2003-10-28 | 1082.94x |
| 2003-10-27 | 1126.32x |
| 2003-10-24 | 1191.39x |
| 2003-10-23 | 1191.39x |
| 2003-10-22 | 1137.16x |
| 2003-10-21 | 1137.16x |
| 2003-10-20 | 1115.47x |
| 2003-10-17 | 1104.63x |
| 2003-10-16 | 1191.39x |
| 2003-10-15 | 1169.70x |
